[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/atarabio” connections=”true” suffix=””]

Ataras off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Ataras T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Ataras most advanced T-cell immunotherapy in development, tab-cel_ (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed rituximab, as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

Pipeline

tab-cel_, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed rituximab, as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

In Feb 2015, FDA granted tab-cel_ Breakthrough Therapy Designation for EBV+ PTLD following allogeneic hematopoietic cell transplant.

ATA520 is a cytotoxic T lymphocyte (CTL) product candidate that is precision targeted against the tumor associated antigen, wilms tumor 1 (WT1), and is being studied as a treatment for hematologic malignancies including multiple myeloma (MM) and plasma cell leukemia (PCL) in Phase 1 clinical trials.

Atara ATA274 is precision targeted against antigens expressed by the cytomegalovirus (CMV) using our selectively enhanced targeting technology. This product candidate is being studied for use as a treatment for Glioblastoma multiforme (GBM).